Prior research has demonstrated the involvement of FLT3LG in the activation of CD4+ and CD8+ T cells, consequently impacting the prognosis of AML patients [15], and reduced levels of FLT3LG have been proposed as a diagnostic marker for cervical cancer and have been found to be correlated with the extent of immune cell infiltration within the tumor [34]. This evidence concerns the gene CD8A and acute myeloid leukemia.